



DRAFT PROGRAM OUTLINE

DRAFT AS OF 18 JANUARY 2024 – WATCH FOR REGULAR UPDATES & NEW SPEAKERS!

DAY I - 14 FEBRUARY

08:15 REGISTRATION OPENS - WELCOME COFFEE & NETWORKING

09:00 Initial Welcome Remarks

- Christian J. Suojanen, Founder & CEO - Broadreach Global
- Pieter Van Bokhoven, Chief Scientific Officer, Amsterdam Neuroscience IAO - VUMC

09:15 CNS Neurosciences and Psychiatry – the need for a new generation of novel therapeutics and the policy and ecosystem requirements to accelerate development.

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Pawel Świeboda, Founder, NeuroCentury
- Frédéric Destrebecq, Executive Director – European Brain Council (EBC), Brussels
- Martien Kas, President, European College of NeuroPsychopharmacology (ECNP)

09:45 From outward symptoms to underlying biology – where the science is going in neurodegenerative and psychiatric diseases.

Moderator: Juan Carlos Lopez, Managing Director Research Grants – RTW Charitable Foundation

- Stacie Weninger, Executive Director, F-Prime Biomedical Research Initiative
- Joachim Scholpp, Global Head Translational Medicine, CNS & Emerging Areas, Boehringer Ingelheim
- Pieter Van Bokhoven, Chief Scientific Officer, Amsterdam Neuroscience IAO – VUMC
- Jim Sullivan, Chief Executive Officer - Vanqua Biosciences

10:30 COFFEE & NETWORKING BREAK

11:15 Panel Discussion – Panel discussion on enhancing patient selection and clinical trials design for rational drug development in Neurodegeneration.

Moderator: Kalpana Merchant, CSO – Retromer Therapeutics, Adjunct Professor of Neurology – northwestern University Feinberg School of Medicine

- Martien Kas, President, European College of NeuroPsychopharmacology (ECNP)
- Philip Scheltens, EQT Dementia Fund



12:00 Discussion Panel – The move to increasing precision medicine approaches in psychiatry

- Joachim Scholpp, Global Head Translational Medicine, CNS & Emerging Areas, Boehringer Ingelheim
- Kees Been, CEO – Kynexis Therapeutics

12:45 LUNCH & NETWORKING BREAK

13:45 Investor Session - The early-stage CNS neuroscience investor perspective.
Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Raúl Martín-Ruiz, Partner - Ysios Capital.
- David Reynolds, Venture Partner – Dementia Discovery Fund
- Sourav Kole, Managing Director – Dolby Family Ventures
- Stacie Weninger, Executive Director, F-Prime Biomedical Research Initiative
- Hakan Goker, Managing Director – M-Ventures

14:30 COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.

- Pitches are 3 minutes, followed by 3 minutes Q&A led by the jury.
- Companies then have dedicated meeting space for follow up discussions, in the networking break which follows.

15:15 COFFEE & NETWORKING BREAK

15:45 Gene therapy, RNA and advanced therapies in Neurodegenerative Disease.

- José Luis Lanciego, Chair – International Brain Research Organization Pan European Committee, Head – Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program – CIMA, University of Navarra
- Kalpana Merchant, CSO – Retromer Therapeutics
- Jason Dichtenberg, CEO, Stealth Biotech
- Dee Datta, CEO, Switch Therapeutics
- Maria Luisa Pineda, Co-Founder & CEO – Envisagenics

16:45 COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.

- Pitches are 3 minutes, followed by 3 minutes Q&A led by the jury.
- Companies then have dedicated meeting space for follow up discussions, in the networking break which follows.

17:30 END OF DAY I PROGRAM & NETWORKING RECEPTION



DAY II - 15 FEBRUARY

08:15 REGISTRATION OPENS - WELCOME COFFEE & NETWORKING

09:00 Opening Remarks

09:15 Advanced therapeutics for rare neurological diseases – the potential, challenges, and strategies for success.

Moderator: Juan Carlos Lopez, Managing Director, Research Grants – RTW Charitable Foundation

- Yael Weiss, CEO - Mahzi
- Terry Pirovolakis, Founder & CEO – Elpida Therapeutics
- Javier Garcia, General Partner & Founder, Columbus Venture Partners (*to be confirmed*)

10:00 Growth company panel: Advancing the pipeline and navigating current market conditions.

Moderator: Cillian King, Managing Director – EQT Life Sciences

- Mary Chamberlain-Tharp, Chief Business Officer – Neumora
- Carlos Buesa, Founder & Chairman of the Board - Oryzon
- Craig Thompson, CEO, Cerevance
- Nils Plath, Chief Scientific Officer - Muna Therapeutics

10:45 COFFEE & NETWORKING BREAK

11:15 Industry Panel – Partnering with Industry on CNS neuroscience drug development

- Christian Thomsen, Global Head CNS Business Development & Licensing, Boehringer Ingelheim, Germany
- Olga Krylova, Director of Business Development & Innovation, Otsuka Pharmaceutical Companies Europe

12:15 COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.

- Pitches are 3 minutes, followed by 3 minutes Q&A led by the jury.
- Companies then have dedicated meeting space for follow up discussions, in the networking break which follows.

13:00 NETWORKING LUNCH – Exhibition area



14:00 The state of CNS neuroscience drug development, science and investment.

- Philip Scheltens, Head of the Dementia Fund, Partner – EQT Life Sciences

14:15 Investor Session – biopharma VCs, CNS neuroscience is back.

Moderator: Christian J. Suojanen, Founder & CEO - Broadreach Global

- Philip Scheltens, Head of the Dementia Fund, Partner – EQT Life Sciences
- Kostia Adamsky, COO & Co-Founder - NEGEV Capital
- Thierry Laugel, Managing Partner, Kurma Partners

15:00 Wrap up Discussion with the Advisory Board

15:30 Bio-Neuroscience Pitch Award – As selected by the investor and industry jury.

15:45 WRAP & CLOSING REMARKS

END OF SUMMIT - NETWORKING